|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023.PubMed/NCBI
|
|
3
|
Dyba T, Randi G, Bray F, Martos C, Giusti
F, Nicholson N, Gavin A, Flego M, Neamtiu L, Dimitrova N, et al:
The European cancer burden in 2020: Incidence and mortality
estimates for 40 countries and 25 major cancers. Eur J Cancer.
157:308–347. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cervantes A, Adam R, Roselló S, Arnold D,
Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino
T, et al: Metastatic colorectal cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up. Ann Oncol.
34:10–32. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tabernero J, Grothey A, Van Cutsem E,
Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F,
Hong YS, et al: Encorafenib Plus Cetuximab as a new standard of
care for previously treated BRAF V600E-mutant metastatic colorectal
cancer: Updated survival results and subgroup analyses from the
BEACON study. J Clin Oncol. 39:273–284. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Santini D, Botticelli A, Galvano A,
Iuliani M, Incorvaia L, Gristina V, Taffon C, Foderaro S,
Paccagnella E, Simonetti S, et al: Network approach in liquidomics
landscape. J Exp Clin Cancer Res. 42:1932023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lièvre A, Merlin JL, Sabourin JC, Artru P,
Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza
RA, et al: RAS mutation testing in patients with metastatic
colorectal cancer in French clinical practice: A status report in
2014. Dig Liver Dis. 50:507–512. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomsen CB, Hansen TF, Andersen RF,
Lindebjerg J, Jensen LH and Jakobsen A: Monitoring the effect of
first line treatment in RAS/RAF mutated metastatic colorectal
cancer by serial analysis of tumor specific DNA in plasma. J Exp
Clin Cancer Res. 37:552018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Allegretti M, Cottone G, Carboni F,
Cotroneo E, Casini B, Giordani E, Amoreo CA, Buglioni S, Diodoro M,
Pescarmona E, et al: Cross-sectional analysis of circulating tumor
DNA in primary colorectal cancer at surgery and during post-surgery
follow-up by liquid biopsy. J Exp Clin Cancer Res. 39:692020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taly V, Pekin D, Benhaim L, Kotsopoulos
SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K,
et al: Multiplex picodroplet digital PCR to detect KRAS mutations
in circulating DNA from the plasma of colorectal cancer patients.
Clin Chem. 59:1722–1731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thierry AR, Mouliere F, El Messaoudi S,
Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte
P, Robert B, et al: Clinical validation of the detection of KRAS
and BRAF mutations from circulating tumor DNA. Nat Med. 20:430–435.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Van Cutsem E, Lenz HJ, Köhne CH, Heinemann
V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken
JH and Ciardiello F: Fluorouracil, leucovorin, and irinotecan plus
cetuximab treatment and RAS mutations in colorectal cancer. J Clin
Oncol. 33:692–700. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bokemeyer C, Bondarenko I, Hartmann JT, de
Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski
P: Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
The OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siravegna G, Marsoni S, Siena S and
Bardelli A: Integrating liquid biopsies into the management of
cancer. Nat Rev Clin Oncol. 14:531–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Franczak C, Witz A, Geoffroy K, Demange J,
Rouyer M, Husson M, Massard V, Gavoille C, Lambert A, Gilson P, et
al: Evaluation of KRAS, NRAS and BRAF mutations detection in plasma
using an automated system for patients with metastatic colorectal
cancer. PLoS One. 15:e02272942020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Franczak C, Dubouis L, Gilson P, Husson M,
Rouyer M, Demange J, Leroux A, Merlin JL and Harlé A: Integrated
routine workflow using next-generation sequencing and a
fully-automated platform for the detection of KRAS, NRAS and BRAF
mutations in formalin-fixed paraffin embedded samples with poor DNA
quality in patients with colorectal carcinoma. PLoS One.
14:e02128012019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Witz A, Dardare J, Betz M, Gilson P,
Merlin JL and Harlé A: Tumor-derived cell-free DNA and circulating
tumor cells: Partners or rivals in metastasis formation? Clin Exp
Med. 24:22024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
García-Foncillas J, Tabernero J, Élez E,
Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R,
Muinelo-Romay L, Montagut C, et al: Prospective multicenter
real-world RAS mutation comparison between OncoBEAM-based liquid
biopsy and tissue analysis in metastatic colorectal cancer. Br J
Cancer. 119:1464–1470. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Osumi H, Takashima A, Ooki A, Yoshinari Y,
Wakatsuki T, Hirano H, Nakayama I, Okita N, Sawada R, Ouchi K, et
al: A multi-institutional observational study evaluating the
incidence and the clinicopathological characteristics of NeoRAS
wild-type metastatic colorectal cancer. Transl Oncol.
35:1017182023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thierry AR, El Messaoudi S, Mollevi C,
Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C,
Mathonnet M, et al: Clinical utility of circulating DNA analysis
for rapid detection of actionable mutations to select metastatic
colorectal patients for anti-EGFR treatment. Ann Oncol.
28:2149–2159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vivancos A, Aranda E, Benavides M, Élez E,
Gómez-España MA, Toledano M, Alvarez M, Parrado MRC,
García-Barberán V and Diaz-Rubio E: Comparison of the clinical
sensitivity of the Idylla platform and the OncoBEAM RAS CRC assay
for KRAS Mutation detection in liquid biopsy samples. Sci Rep.
9:89762019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grasselli J, Elez E, Caratù G, Matito J,
Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, et
al: Concordance of blood- and tumor-based detection of RAS
mutations to guide anti-EGFR therapy in metastatic colorectal
cancer. Ann Oncol. 28:1294–1301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vidal J, Muinelo L, Dalmases A, Jones F,
Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E,
et al: Plasma ctDNA RAS mutation analysis for the diagnosis and
treatment monitoring of metastatic colorectal cancer patients. Ann
Oncol. 28:1325–1332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bando H, Kagawa Y, Kato T, Akagi K, Denda
T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, et al: A
multicentre, prospective study of plasma circulating tumour DNA
test for detecting RAS mutation in patients with metastatic
colorectal cancer. Br J Cancer. 120:982–986. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Velimirovic M, Juric D, Niemierko A,
Spring L, Vidula N, Wander SA, Medford A, Parikh A, Malvarosa G,
Yuen M, et al: Rising circulating tumor DNA as a molecular
biomarker of early disease progression in metastatic breast cancer.
JCO Precis Oncol. 4:1246–1262. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mauri G, Vitiello PP, Sogari A, Crisafulli
G, Sartore-Bianchi A, Marsoni S, Siena S and Bardelli A: Liquid
biopsies to monitor and direct cancer treatment in colorectal
cancer. Br J Cancer. 127:394–407. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loupakis F, Sharma S, Derouazi M, Murgioni
S, Biason P, Rizzato MD, Rasola C, Renner D, Shchegrova S, Koyen
Malashevich A, et al: Detection of molecular residual disease using
personalized circulating tumor DNA assay in patients with
colorectal cancer undergoing resection of metastases. JCO Precis
Oncol. 5:PO.21.00101. 2021.PubMed/NCBI
|
|
32
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Turner NC, Swift C, Jenkins B, Kilburn L,
Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek
P, et al: Results of the c-TRAK TN trial: A clinical trial
utilising ctDNA mutation tracking to detect molecular residual
disease and trigger intervention in patients with moderate- and
high-risk early-stage triple-negative breast cancer. Ann Oncol.
34:200–211. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Powles T, Assaf ZJ, Davarpanah N,
Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S,
Gschwend JE, et al: ctDNA guiding adjuvant immunotherapy in
urothelial carcinoma. Nature. 595:432–743. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y,
Kosmider S, Wong R, Shapiro J, Lee M, Harris S, et al: Circulating
tumor DNA analysis guiding adjuvant therapy in stage II colon
cancer. N Engl J Med. 386:2261–2272. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taniguchi H, Nakamura Y, Kotani D, Yukami
H, Mishima S, Sawada K, Shirasu H, Ebi H, Yamanaka T, Aleshin A, et
al: CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform
trials to refine adjuvant therapy for colorectal cancer. Cancer
Sci. 112:2915–2920. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pascual J, Attard G, Bidard FC, Curigliano
G, Mattos-Arruda LD, Diehn M, Italiano A, Lindberg J, Merker JD,
Montagut C, et al: ESMO recommendations on the use of circulating
tumour DNA assays for patients with cancer: A report from the ESMO
Precision Medicine Working Group. Ann Oncol. 33:750–768. 2022.
View Article : Google Scholar : PubMed/NCBI
|
